| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 50 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64, 65+ |
| Body Types | Obese |
Supplementation of chromium picolinate at 500mcg or 1,000mcg for six months in persons at risk for type II diabetes has failed to influence any biomarkers of glucose metabolism and was said to not confer any protection against the development of type II diabetes.
